MOTIVATE-C: a randomised trial to evaluate the impact of financial incentives on the rate of initiation of antiviral therapy in people with hepatitis C

Not Applicable

Recruiting

• Conditions: Hepatitis C; Infection - Other infectious diseases

• Registration Number: ACTRN12623000024640
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-01-11
• Last Update Posted: 6 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1300

Inclusion Criteria

Adults (18 years or older) with current hepatitis C infection (by self-report) who are Medicare-eligible and living in Australia.
The co-incentive payment for the provider will be allocated as part of the participant's randomisation. The primary care provider is not a 'participant' in this project and therefore there are no specific inclusion criteria. The primary care provider can either be nominated by the participant or, in the absence of a preferred provider, can be selected by the participant from a pre-specified list of primary care providers.

Exclusion Criteria

A potentially eligible individual will be excluded if they:
• Are already receiving DAA therapy for hepatitis C infection or have received DAA therapy in the previous 6 months
• Have previously enrolled in the project
• Are unable or unwilling to provide informed consent
• Are unable or unwilling to complete follow-up
• Are unable to commence treatment within 12 weeks of randomisation due to a contra-indication (e.g., pregnancy, or breastfeeding)

The co-incentive payment for the provider will be allocated as part of the participant's randomisation. The primary care provider is not a 'participant' in this project and therefore there are no specific exclusion criteria.

Study & Design

• Study Type: Interventional
• Study Design: Not specified